BioTime (BTX) Posts Q3 EPS of 30c
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil steadies after surge following reported Israeli attack on Iran
- Reports of Israeli attack on Iran spark rush to Swiss franc and yen
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Asterias Biotherapeutics to Report Third Quarter Results on November 14, 2016
November 4, 2016 7:00 AM EDTFREMONT, Calif., Nov. 4, 2016 /PRNewswire/ --Â Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release third quarter financial results and provide an update on clinical progress on Monday, November 14, 2016 after the close of the U.S. financial markets.
The Company will host a conference call and webcast on November 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Company management will be joined by Shekar N. Kurpad, MD, PhD, Professor of Neurosurgery, Director, Spinal Cord Injury Center Medical College of... More
BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
November 3, 2016 4:01 PM EDTInitial data from OpRegen® trial suggest cells able to engraft and survive at least 12 months Initial 3-D Imaging data from Renevia® trial run-in patients suggest volumetric improvements are sustained at least 12 months
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent cell-based technologies, today reported financial results for the third quarter ended September 30, 2016, and recent therapeutic program progress.
Through the quarter, we continued... More